Effectiveness of the probiotic Bacillus subtilis DG101 to treat type 2 diabetes mellitus triggered by SARS‑CoV‑2 infection

Authors:
  • FAFacundo Rodriguez Ayala
    Facundo Rodriguez Ayala
  • NCNestor Cardinali
    Nestor Cardinali
  • RGRoberto Grau
    Roberto Grau
  • R1Rosario (2000) Instituto Cardinali de Nutrición. 9 de Julio 1287
    Rosario (2000) Instituto Cardinali de Nutrición. 9 de Julio 1287
  • R5Rosario (2000) Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas Y Farmacéuticas. Consejo Nacional de Investigaciones Científicas Y Técnicas (Conicet). Suipacha 531
    Rosario (2000) Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas Y Farmacéuticas. Consejo Nacional de Investigaciones Científicas Y Técnicas (Conicet). Suipacha 531

Abstract
The spore-forming probiotic Bacillus subtilis DG101 have proven to be an effective adjuvant intervention in the treatment of type 2 diabetes mellitus originally refractory to conventional therapy with metformin. Since the COVID-19 is able to trigger type 1 and type 2 diabetes mellitus which may not respond to medication and / or insulin levels, we were intrigued to unveil if B. subtilis DG101 probiotic intervention would be able to restored the physiological level of glucose and HbA1c among patients recovered from COVID-19. Herein, we report three cases of SARS-CoV-2-triggered type 2 diabetes mellitus resistant to insulin and metformin treatment in overweight patients which successfully responded to the incorporation of the probiotic B. subtilis DG101to the anti-diabetic therapy.